Advertisement


Catherine Thieblemont, MD, PhD, and Julie Vose, MD, MBA, on DLBCL: Results From the Lysa Remarc Study

2016 ASH Annual Meeting & Exposition

Advertisement

Catherine Thieblemont, MD, PhD, of Hôpital Saint-Louis and INSERM, and Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discuss phase III trial findings on lenalidomide maintenance in elderly patients with DLBCL treated with R-CHOP in the first-line setting (Abstract 471).



Related Videos

Lymphoma

Laurie H. Sehn, MD, MPH, on Follicular Lymphoma: Choosing the Best Target

Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses agents in the pipeline for follicular lymphoma, including drugs targeting the immune microenvironment, novel ...

Hematologic Malignancies

Joshua Brody, MD, on Lymphoid Malignancies: Immunotherapy Update

Joshua Brody, MD, of the Icahn School of Medicine at Mount Sinai, summarizes important data on passive and active immunotherapy (Abstracts 1213, 1214, 1215, 1216, 1217, 1218).

Leukemia

Martin Schrappe, MD, on Childhood ALL: Study Results on Reducing Treatment Burden

Martin Schrappe, MD, of Christian-Albrechts University Kiel, discusses study findings on reduced intensity delayed intensification in standard-risk patients defined by minimal residua...

Leukemia

Jose F. Leis, MD, PhD, and Sagar Lonial, MD, on CLL: Ibrutinib Insights

Jose F. Leis, MD, PhD, of the Mayo Clinic, and Sagar Lonial, MD, of Emory University, discuss a session on CLL treatment (excluding transplantation): ibrutinib resist...

Leukemia

Julie Vose, MD, MBA, and Mhairi Copland, MB, ChB, PhD, on CML: Data From the British DESTINY Study

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Mhairi Copland, MB, ChB, PhD, of the Paul O’Gorman Leukaemia Research Centre at the University ...

Advertisement

Advertisement



Advertisement